|

TNhYP217 CAR T Cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Colonic Neoplasms1
  • Thymus Neoplasms1
  • Ovarian Neoplasms1
  • Pancreatic Neoplasms1
  • Neoplasms1

Bethesda, Maryland1 trial

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

National Institutes of Health Clinical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.